1. Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol. 2006; 175(3 Pt 2): S5-10. DOI: 10.1016/S0022-5347(05)00313-7 [
DOI:10.1016/S0022-5347(05)00313-7]
2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010; 21(1): 5-26. DOI: 10.1007/s00192-009-0976-9 [
DOI:10.1007/s00192-009-0976-9]
3. Abello A, Das AK. Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects. Ther Adv Urol. 2018; 10(5): 165-73. DOI: 10.1177/1756287218756082 [
DOI:10.1177/1756287218756082]
4. Sayner AM, Rogers F, Tran J, Jovanovic E, Henningham L, Nahon I. Transcutaneous Tibial Nerve Stimulation in the Management of Overactive Bladder: A Scoping Review. Neuromodulation. 2022; 25(8): 1086-96. DOI: 10.1016/j.neurom.2022.04.034 [
DOI:10.1016/j.neurom.2022.04.034]
5. Al-Danakh A, Safi M, Alradhi M, Almoiliqy M, Chen Q, Al-Nusaif M, et al. Posterior Tibial Nerve Stimulation for Overactive Bladder: Mechanism, Classification, and Management Outlines. Parkinsons Dis. 2022; 2022: 2700227. DOI: 10.1155/2022/2700227 [
DOI:10.1155/2022/2700227]
6. Caldwell KP. The electrical control of sphincter incompetence. Lancet. 1963; 2(7300): 174-5. DOI: 10.1016/s0140-6736(63)92807-1 [
DOI:10.1016/S0140-6736(63)92807-1]
7. Bapir R, Bhatti KH, Eliwa A, Garcia-Perdomo HA, Gherabi N, Hennessey D, et al. Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials. Arch Ital Urol Androl. 2022; 94(4): 492-506. DOI: 10.4081/aiua.2022.4.492 [
DOI:10.4081/aiua.2022.4.492]
8. Govier FE, Litwiller S, Nitti V, Kreder KJ, Jr., Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001; 165(4): 1193-8. PMID: 11257669 [
DOI:10.1016/S0022-5347(05)66469-5]
9. Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010; 184(5): 2001-6. DOI: 10.1016/j.juro.2010.06.113 [
DOI:10.1016/j.juro.2010.06.113]
10. Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010; 75(1): 62-8. DOI: 10.1016/j.urology.2009.09.018 [
DOI:10.1016/j.urology.2009.09.018]
11. Martin-Garcia M, Crampton J. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). Physiotherapy. 2019; 105(4): 469-75. DOI: 10.1016/j.physio.2018.12.002 [
DOI:10.1016/j.physio.2018.12.002]
12. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010; 183(4): 1438-43. DOI: 10.1016/j.juro.2009.12.036 [
DOI:10.1016/j.juro.2009.12.036]
13. Yoong W, Shah P, Dadswell R, Green L. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders. Int Urogynecol J. 2013; 24(5): 795-9. DOI: 10.1007/s00192-012-1936-3 [
DOI:10.1007/s00192-012-1936-3]